Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE. Cirkel GA, et al. Among authors: bins s. Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27. Ann Oncol. 2016. PMID: 27234642 Free article. Clinical Trial.
Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.
Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group. Verheijen RB, et al. Among authors: bins s. Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. doi: 10.1158/1078-0432.CCR-16-1255. Epub 2016 Jul 28. Clin Cancer Res. 2016. PMID: 27470967
Capecitabine and the Risk of Fingerprint Loss.
van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R. van Doorn L, et al. Among authors: bins s. JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638. JAMA Oncol. 2017. PMID: 27560202 No abstract available.
54 results